Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
Name | Price | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nurulimab Biosimilar - Anti-CTLA4 mAb - Research Grade | Login | Nurulimab Biosimilar - Anti-CTLA4 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Pacmilimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | Login | Pacmilimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Pacmilimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | Login | Pacmilimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Veltuzumab Biosimilar - Anti- CD20 receptors mAb - Research Grade | Login | Veltuzumab Biosimilar - Anti- CD20 receptors mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Veltuzumab Biosimilar - Anti- CD20 receptors mAb - Research Grade | Login | Veltuzumab Biosimilar - Anti- CD20 receptors mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Ibritumomab Biosimilar - Anti-MS4A1(CD20,MS4A-1) mAb - Research Grade | Login | Ibritumomab Biosimilar - Anti-MS4A1(CD20,MS4A-1) mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Ibritumomab Biosimilar - Anti-MS4A1(CD20,MS4A-1) mAb - Research Grade | Login | Ibritumomab Biosimilar - Anti-MS4A1(CD20,MS4A-1) mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Brentuximab Biosimilar - Anti-TNFRSF8 mAb - Research Grade | Login | Brentuximab Biosimilar - Anti-TNFRSF8 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Brentuximab Biosimilar - Anti-TNFRSF8 mAb - Research Grade | Login | Brentuximab Biosimilar - Anti-TNFRSF8 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Moxetumomab Biosimilar - Anti-CD22 mAb - Research Grade | Login | Moxetumomab Biosimilar - Anti-CD22 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Moxetumomab Biosimilar - Anti-CD22 mAb - Research Grade | Login | Moxetumomab Biosimilar - Anti-CD22 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Lemzoparlimab Biosimilar - Anti-CD47 mAb - Research Grade | Login | Lemzoparlimab Biosimilar - Anti-CD47 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Lemzoparlimab Biosimilar - Anti-CD47 mAb - Research Grade | Login | Lemzoparlimab Biosimilar - Anti-CD47 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Cosibelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | Login | Cosibelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Cosibelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | Login | Cosibelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Glofitamab Biosimilar - Anti-CD3E, MS4A1 mAb - Research Grade | Login | Glofitamab Biosimilar - Anti-CD3E, MS4A1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Manelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | Login | Manelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Manelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | Login | Manelimab Biosimilar - Anti-CD274, PD-L1, B7-H1 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
TMPRSS2 | Login | TMPRSS2 | ||||||||||||||||
|
||||||||||||||||||
TMPRSS2 | Login | TMPRSS2 | ||||||||||||||||
|
||||||||||||||||||
A. thaliana AteIF4E1 Recombinant Protein | Login | A. thaliana AteIF4E1 Recombinant Protein | ||||||||||||||||
|
||||||||||||||||||
A. thaliana HSP17 Recombinant Protein | Login | A. thaliana HSP17 Recombinant Protein | ||||||||||||||||
|
||||||||||||||||||
Chilli Ca_eIF4E1 Recombinant Protein | Login | Chilli Ca_eIF4E1 Recombinant Protein | ||||||||||||||||
|
||||||||||||||||||
Ciona intestinalis MYO5 Recombinant Protein | Login | Ciona intestinalis MYO5 Recombinant Protein | ||||||||||||||||
|
||||||||||||||||||
Human APP (18-690) Recombinant Protein | Login | Human APP (18-690) Recombinant Protein | ||||||||||||||||
|